Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
136
Recruiting, any sponsor type, condition "type 1 diabetes"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting136
- Completed1,365
136 trials
Showing 1 to 25, recently updated first.
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 DiabetesPivotal-lookingRecruiting
City of Hope Medical CenterAcademic, hospital or other
NCT07061574 · 120 participants (planned) · Start Mar 10, 2026 · Primary completion Apr 15, 2030
Drug: Anti-thymocyte globulin (ATG); verapamil extended-release capsule and 1 more · For: Type 1 Diabetes; New Onset
Sites: Los Angeles, California; San Francisco, California; New Haven, Connecticut · 11 sites in all
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalAcademic, hospital or other
NCT07951658 · 12 participants (planned) · Start Sep 27, 2026 · Primary completion Oct 2028
Drug: Tirzepatide · For: Diabetes Type I
Sites: Madrid, Spain
- Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous SemaglutidePivotal-lookingRecruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT06387199 · 33 participants (planned) · Start Dec 1, 2024 · Primary completion Dec 2027
Drug: Semaglutide with 4 meal strategies; Placebo with 4 meal strategies · For: Type 1 Diabetes; Diabetes Mellitus
Sites: Montreal, Canada
- GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)Recruiting
Eddingpharm (Zhuhai) Co., Ltd.Industry
NCT07738341 · 270 participants (planned) · Start Jul 28, 2026 · Primary completion Aug 1, 2029
Drug: GB268; Nab-Paclitaxel and 2 more · For: Breast Cancer (Locally Advanced or Metastatic)
Sites: Beijing, China
- A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07881887 · 617 participants (planned) · Start Oct 22, 2026 · Primary completion Mar 2029
Drug: LY4167586; Placebo · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Rogers, Arkansas; Anaheim, California; Los Alamitos, California · 15 sites in all
- A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06945406 · 124 participants (planned) · Start May 16, 2025 · Primary completion Jul 2027
Drug: LY4057996 SC; LY4057996 IV and 6 more · For: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Sites: Neuss, Germany
University of FloridaAcademic, hospital or other
NCT06455319 · 60 participants (planned) · Start Nov 12, 2025 · Primary completion Nov 2028
Drug: Anti-thymocyte globulin (ATG); verapamil extended release capsule · For: Type 1 Diabetes
Sites: Aurora, Colorado; Gainesville, Florida
Op-T LLCIndustry
NCT06964087 · 72 participants (planned) · Start Apr 23, 2026 · Primary completion May 31, 2027
Drug: OPT101 · For: Type I Diabetes
Sites: Birmingham, Alabama; Walnut Creek, California; Aurora, Colorado · 5 sites in all
- PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) StudyPivotal-lookingRecruiting
University of FloridaAcademic, hospital or other
NCT07670650 · 108 participants (planned) · Start Nov 10, 2026 · Primary completion Mar 1, 2029
Drug: SAB-142; Placebo · For: Type 1 Diabetes (T1D)
Sites: San Francisco, California; Aurora, Colorado; Gainesville, Florida · 4 sites in all
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)Pivotal-lookingRecruiting
Viking Therapeutics, Inc.Industry
NCT07868835 · 560 participants (planned) · Start Nov 2026 · Primary completion Jul 2028
Drug: VK2735; Placebo comparator · For: Weight Loss
Sites: Tucson, Arizona; Chula Vista, California; Lake Forest, California · 20 sites in all
- A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07088068 · 723 participants (planned) · Start Aug 6, 2025 · Primary completion Jun 6, 2028
Drug: Teplizumab · For: Type 1 Diabetes Mellitus
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 201 sites in all
- Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon CancerPivotal-lookingRecruiting
Solstice Oncology, Inc.Industry
NCT07808151 · 100 participants (planned) · Start Nov 30, 2026 · Primary completion Sep 30, 2029
Drug: Pembrolizumab; Porustobart · For: Colon Cancer
Sites: Los Angeles, California; Tampa, Florida; Chicago, Illinois · 30 sites in all
COUR Pharmaceutical Development Company, Inc.Industry
NCT06783309 · 72 participants (planned) · Start May 12, 2025 · Primary completion Aug 2027
Drug: CNP-103; Placebo · For: Type 1 Diabetes Mellitus; T1D; T1DM and 7 more
Sites: Tucson, Arizona; Newport Beach, California; San Diego, California · 45 sites in all
vTv TherapeuticsIndustry
NCT07616206 · 40 participants (planned) · Start Sep 29, 2026 · Primary completion Jun 2027
Drug: Cadisegliatin 800 mg QD; Placebo · For: Type 1 Diabetes (T1D)
Sites: Modesto, California; San Diego, California; Aurora, Colorado · 6 sites in all
- A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 DiabetesPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07896109 · 121 participants (planned) · Start Oct 22, 2026 · Primary completion Jul 26, 2028
Drug: NNC9836-0001; Placebo (NaCl) · For: Diabetes Mellitus, Type 2
Sites: Neuss, Germany
- Permissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM)Recruiting
Ohio State UniversityAcademic, hospital or other
NCT07293715 · 44 participants (planned) · Start Feb 25, 2026 · Primary completion Jun 2027
Drug: Insulin · For: Pregnancy, High Risk; Type 1 Diabetes; Type 2 Diabetes
Sites: Columbus, Ohio
SanofiSanofi (SNY)
NCT07360080 · 1,000 participants (planned) · Start Mar 19, 2026 · Primary completion Oct 29, 2035
Drug: Teplizumab · For: Type 1 Diabetes
Sites: Washington D.C., District of Columbia; Atlanta, Georgia; New York, New York · 12 sites in all
- A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07776509 · 500 participants (planned) · Start Aug 24, 2026 · Primary completion Aug 9, 2028
Drug: Lenbelintide; Placebo · For: Obesity or Overweight; Weight-Related Comorbidity; With/Without Diabetes Mellitus, Type 2
Sites: Escondido, California; Lincoln, California; Walnut Creek, California · 96 sites in all
SanofiSanofi (SNY)
NCT07457580 · 60 participants (planned) · Start Mar 16, 2026 · Primary completion Nov 30, 2026
Drug: Teplizumab · For: Type 1 Diabetes
Sites: Leuven, Belgium; Bron, France; Paris, France · 16 sites in all
- Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaPivotal-lookingRecruiting
Biocon Biologics UK PLCIndustry
NCT07476326 · 120 participants (planned) · Start Sep 9, 2026 · Primary completion Aug 16, 2027
Drug: Bmab1700; Opdivo · For: Melanoma
Sites: Bento Gonçalves, Brazil; Ijuí, Brazil; Pará, Brazil · 46 sites in all
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and AdultsPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07222137 · 150 participants (planned) · Start Jan 12, 2026 · Primary completion Jul 2031
Drug: Baricitinib; Placebo · For: Diabetes Mellitus, Type 1
Sites: Santa Barbara, California; Tallahassee, Florida; Iowa City, Iowa · 112 sites in all
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07222332 · 300 participants (planned) · Start Feb 5, 2026 · Primary completion Jul 2028
Drug: Baricitinib; Placebo · For: Diabetes Mellitus, Type 1
Sites: Aurora, Colorado; Tallahassee, Florida; Philadelphia, Pennsylvania · 130 sites in all
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07784725 · 2,500 participants (planned) · Start Aug 19, 2026 · Primary completion Aug 11, 2028
Drug: Lenbelintide; Placebo · For: Obesity or Overweight
Sites: Dothan, Alabama; Huntsville, Alabama; Mesa, Arizona · 220 sites in all
Centre Hospitalier Universitaire DijonAcademic, hospital or other
NCT03512132 · 200 participants (planned) · Start Apr 24, 2018 · Primary completion Oct 2027
Drug: Blood samples; Urine sample · For: Type 1 Diabetes
Sites: Dijon, France
NYU Langone HealthAcademic, hospital or other
NCT05641753 · 125 participants (planned) · Start Dec 6, 2022 · Primary completion Jul 1, 2027
Drug: Evolocumab Cartridge; Atorvastatin Calcium Tablets and 2 more · For: Type 1 Diabetes
Sites: New York, New York · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.